Effective combination gene therapy using CEACAM6-shRNA and the fusion suicide gene yCDglyTK for pancreatic carcinoma in vitro

Long,Hongyu; Li,Qingfu; Wang,Yuan; Li,Qian; Liu,Ting; Peng,Jie

doi:10.3892/etm.2012.774

Effective combination gene therapy using CEACAM6-shRNA and the fusion suicide gene yCDglyTK for pancreatic carcinoma in vitro

Authors:
- Hongyu Long
- Qingfu Li
- Yuan Wang
- Qian Li
- Ting Liu
- Jie Peng
View Affiliations

Affiliations: Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: October 30, 2012 https://doi.org/10.3892/etm.2012.774
Pages: 155-161

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of pancreatic carcinoma, a gastrointestinal malignancy, is on the increase and effective therapeutic strategies are therefore required. This study aimed to construct a recombinant plasmid pcDNA3.1(-)shCEACAM6-yCDglyTK from CEACAM6 targeting shRNA and the fusion suicide gene yCDglyTK for inhibition of SW1990 human pancreatic carcinoma cell growth and invasion. A plasmid containing hU6 promoter and CEACAM6 targeting short hairpin RNA (CEACAM6-shRNA) frame was constructed. It was subcloned to a CEA promoter-driven fusion suicide gene pcDNA3.1(-)yCDglyTK. The recombinant plasmid pcDNA3.1(-)shCEACAM6-yCDglyTK was identified by restriction endonuclease analysis and DNA sequencing. The recombinant plasmid was delivered into SW1990 human pancreatic carcinoma cells, the mRNA and protein expression of yCDglyTK and CEACAM6 was examined by RT-PCR, western blot analysis and immunofluorescence. SW1990 cells were treated with the prodrug 5-fluorocytosine (5-FC), and the cell viability was evaluated using the 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. The invasiveness and migration of SW1990 cells were evaluated by transwell migration assays. The restriction endonuclease analysis and DNA sequencing confirmed the construction of the recombinant plasmid pcDNA3.1(-)shCEACAM6-yCDglyTK. Reverse transcription polymerase chain reaction (RT-PCR) and western blot analysis outcomes showed that yCDglyTK was expressed in SW1990 cells and expression of CEACAM6 in SW1990 cells was significantly knocked down. MTT assay showed that the mean viability of SW1990 cells was significantly reduced after administration of the prodrug 5-FC in vitro. Transwell migration assays showed that invasion and migration action of SW1990 cells was significantly inhibited. In conclusion, recombinant plasmid pcDNA3.1(-)shCEACAM6-yCDglyTK was successfully constructed. The recombinant plasmid may therefore serve as a novel gene therapy approach for pancreatic carcinoma.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 60:277–300. 2010.
2	Bond-Smith G, Banga N, Hammond TM and Imber CJ: Pancreatic adenocarcinoma. BMJ. 344:e24762012. View Article : Google Scholar : PubMed/NCBI
3	Arlt A, Gehrz A, Muerkoster S, et al: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003. View Article : Google Scholar : PubMed/NCBI
4	Stathis A and Moore MJ: Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hedley D, Ogilvie L and Springer C: Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer. 7:870–879. 2007. View Article : Google Scholar : PubMed/NCBI
6	Nawa A, Tanino T, Luo C, et al: Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer. Anticancer Agents Med Chem. 8:232–239. 2008. View Article : Google Scholar
7	Shah K: Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 64:739–748. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ahn YH, Yi H, Shin JY, et al: STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy. Clin Exp Metastasis. 29:359–369. 2012. View Article : Google Scholar : PubMed/NCBI
9	Niu HX, Du T, Xu ZF, Zhang XK and Wang RG: Role of wild type p53 and double suicide genes in interventional therapy of liver cancer in rabbits. Acta Cir Bras. 27:522–528. 2012. View Article : Google Scholar : PubMed/NCBI
10	Barnett T, Goebel SJ, Nothdurft MA and Elting JJ: Carcinoembryonic antigen family: characterization of cDNAs coding for NCA and CEA and suggestion of nonrandom sequence variation in their conserved loop-domains. Genomics. 3:59–66. 1988. View Article : Google Scholar : PubMed/NCBI
11	Kuroki M, Matsushita H, Matsumoto H, Hirose Y, Senba T and Yamamoto T: Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new tumor marker. Anticancer Res. 19:5599–5606. 1999.PubMed/NCBI
12	Blumenthal RD, Hansen HJ and Goldenberg DM: Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res. 65:8809–8817. 2005. View Article : Google Scholar : PubMed/NCBI
13	Poola I, Shokrani B, Bhatnagar R, DeWitty RL, Yue Q and Bonney G: Expression of carcinoembryonic antigen cell adhesion molecule 6 oncoprotein in atypical ductal hyperplastic tissues is associated with the development of invasive breast cancer. Clin Cancer Res. 12:4773–4783. 2006. View Article : Google Scholar
14	Blumenthal RD, Leon E, Hansen HJ and Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 7:22007. View Article : Google Scholar : PubMed/NCBI
15	Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW and Whang EE: Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg. 240:667–676. 2004.PubMed/NCBI
16	Strickland LA, Ross J, Williams S, et al: Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol. 218:380–390. 2009. View Article : Google Scholar : PubMed/NCBI
17	Liu T, Zhang G, Chen Y, et al: Tissue specific expression of suicide genes delivered by nanoparticles inhibits gastric carcinoma growth. Cancer Biol Ther. 5:1683–1690. 2006. View Article : Google Scholar : PubMed/NCBI
18	Lee SW, Lee YL, Lee YJ, et al: Enhanced antitumor effects by combination gene therapy using MDR1 gene shRNA and HSV1-tk in a xenograft mouse model. Cancer Lett. 291:83–89. 2010. View Article : Google Scholar : PubMed/NCBI
19	Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 11:2389–2401. 2000. View Article : Google Scholar
20	Boucher PD, Im MM, Freytag SO and Shewach DS: A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 66:3230–3237. 2006. View Article : Google Scholar : PubMed/NCBI
21	Rubsam LZ, Davidson BL and Shewach DS: Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res. 58:3873–3882. 1998.
22	Tomicic MT, Thust R and Kaina B: Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene. 21:2141–2153. 2002. View Article : Google Scholar : PubMed/NCBI
23	Zhang JF, Wei F, Wang HP, et al: Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res. 29:522010. View Article : Google Scholar : PubMed/NCBI
24	Miyagi T, Koshida K, Hori O, et al: Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med. 5:30–37. 2003. View Article : Google Scholar : PubMed/NCBI
25	Kievit E, Bershad E, Ng E, et al: Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 59:1417–1421. 1999.PubMed/NCBI
26	Moriuchi S, Wolfe D, Tamura M, et al: Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther. 9:584–591. 2002. View Article : Google Scholar
27	Hammarstrom S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 9:67–81. 1999. View Article : Google Scholar : PubMed/NCBI
28	Jantscheff P, Terracciano L, Lowy A, et al: Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol. 21:3638–3646. 2003. View Article : Google Scholar : PubMed/NCBI
29	Lewis-Wambi JS, Cunliffe HE, Kim HR, Willis AL and Jordan VC: Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer. 44:1770–1779. 2008. View Article : Google Scholar : PubMed/NCBI
30	Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW and Whang EE: A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res. 64:3987–3993. 2004. View Article : Google Scholar : PubMed/NCBI
31	Ordonez C, Screaton RA, Ilantzis C and Stanners CP: Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 60:3419–3424. 2000.PubMed/NCBI
32	Zhu Z, Sanchez-Sweatman O, Huang X, et al: Anoikis and meta-static potential of cloudman S91 melanoma cells. Cancer Res. 61:1707–1716. 2001.PubMed/NCBI
33	Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene. 23:465–473. 2004. View Article : Google Scholar : PubMed/NCBI
34	Duxbury MS, Ito H, Benoit E, Ashley SW and Whang EE: CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer. 91:1384–1390. 2004. View Article : Google Scholar : PubMed/NCBI
35	Takeichi M: Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 5:806–811. 1993. View Article : Google Scholar : PubMed/NCBI
36	Birchmeier W and Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1198:11–26. 1994.PubMed/NCBI
37	Shi Y: Mammalian RNAi for the masses. Trends Genet. 19:9–12. 2003. View Article : Google Scholar
38	Kuroki M, Matsuo Y, Kinugasa T and Matsuoka Y: Three different NCA species, CGM6/CD67, NCA-95, and NCA-90, are comprised in the major 90 to 100-kDa band of granulocyte NCA detectable upon SDS-polyacrylamide gel electrophoresis. Biochem Biophys Res Commun. 182:501–506. 1992. View Article : Google Scholar : PubMed/NCBI
39	Barnich N, Carvalho FA, Glasser AL, et al: CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest. 117:1566–1574. 2007. View Article : Google Scholar : PubMed/NCBI
40	Carvalho FA, Barnich N, Sivignon A, et al: Crohn’s disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med. 206:2179–2189. 2009.